Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Cervical Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Uterine Cancer (239)

Uterine Cancer (239)

›

No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1	zimberelimab Sensitive: A1 - Approval zimberelimab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	tisotumab vedotin-tftv Sensitive: A1 - Approval tisotumab vedotin-tftv Sensitive : A1	tisotumab vedotin-tftv Sensitive: A1 - Approval tisotumab vedotin-tftv Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-nwgd Sensitive: A1 - Approval bevacizumab-nwgd Sensitive : A1	bevacizumab-nwgd Sensitive: A1 - Approval bevacizumab-nwgd Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1